Mar 20 |
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
|
Mar 4 |
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
|
Feb 28 |
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
|
Feb 26 |
BLRX: Poster Presentations
|
Feb 16 |
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
|
Dec 29 |
BioLineRx files for a $250M mixed securities shelf
|
Dec 21 |
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
|
Dec 4 |
BioLineRx: Still A Buy, With Some Questions
|
Dec 3 |
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
|
Nov 21 |
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript
|